about
Acute and chronic administration of a low-dose combination of topiramate and ondansetron reduces ethanol's reinforcing effects in male alcohol preferring (P) rats.Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings.The role of 5-HT3 receptors in drug abuse and as a target for pharmacotherapy.Therapeutics of 5-HT3 receptor antagonists: current uses and future directions.Clinical neuropharmacology of drugs of abuse: a comparison of drug-discrimination and subject-report measures.Development of medications for alcohol use disorders: recent advances and ongoing challenges.Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people.Treatment implications: using neuroscience to guide the development of new pharmacotherapies for alcoholism.Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders.Management of alcohol misuse in patients with liver diseases.Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol.Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study.Effect of 5-HT3 receptor over-expression on the discriminative stimulus effects of ethanol.[The pharmacologic treatment of the alcohol dependence].Advances in Pharmacotherapy Development: Human Clinical Studies.Behavioral effects and pharmacokinetics of low-dose intravenous alcohol in humans.Effects of moderate and high doses of alcohol on attention, impulsivity, discriminability, and response bias in immediate and delayed memory task performance.
P2860
Q30408317-CE0C8C62-B827-45C1-B870-87D3B3090F4FQ30440516-2861F85A-85A3-43BC-86B9-45DF3B10C96DQ33883890-F064E122-528F-4C57-97AB-CB964B9B2CFCQ35011413-4C50B3D3-C2FB-46F4-B573-91DEA421C4C2Q35684589-57467B2B-285F-436A-BBE1-C080FC0D374DQ36150622-078F357F-B608-4982-AC0E-45178E213234Q36824245-51F3B38E-209A-4836-A61A-46696407C0F8Q37386550-1D7DAC78-337C-4437-9E16-F47A2BFDA05BQ37473457-89806BEE-5B13-4840-9A65-FC2933999B47Q38784465-32534950-9BEC-494F-9EEF-F19B37960BB9Q43940291-987BAA2B-0EB1-4ADF-AD97-0DBDB05649B1Q44524352-FE966616-160B-494C-94B1-1BB210FF188CQ44904372-48BC5999-2A37-4C77-A141-40B778B9FE78Q45281456-BCBBA4F8-0AA7-408D-B028-21EF5FE9CC21Q47182010-7D066811-F9F9-4364-BF49-8A8277B72532Q51535059-9F6EA9C3-AAE1-4FF7-A639-188677D189CDQ52926885-C6E04681-6D44-420B-AE87-2D018B08B39D
P2860
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Ondansetron alters human alcohol intoxication.
@en
Ondansetron alters human alcohol intoxication.
@nl
type
label
Ondansetron alters human alcohol intoxication.
@en
Ondansetron alters human alcohol intoxication.
@nl
prefLabel
Ondansetron alters human alcohol intoxication.
@en
Ondansetron alters human alcohol intoxication.
@nl
P2093
P1476
Ondansetron alters human alcohol intoxication.
@en
P2093
Davidson D
Kuznetsov O
Whelihan W
P304
P356
10.1016/0006-3223(95)00432-7
P407
P577
1996-09-01T00:00:00Z